A Study of RD14-01 in Patients With Advanced Solid Tumors
This study will evaluate the safety and tolerability of RD14-01, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ advanced solid tumors.
Solid Tumor
DRUG: RD14-01 Cell injection
DLT and MTD, Dose-limiting toxicity (DLT) and maximum tolerated dose (MTD), up to 28 days|TEAEs, Adverse events (TEAEs) and incidence after the first infusion, treatment-related adverse events and incidence, adverse events of special concern (AESI) and incidence., up to 12 months
ORR, Overall Response Rate (ORR) by RECIST, version 1.1, up to 28 days|DOR, Duration of response (DOR), up to 12 months|PFS, Progression Free Survival(PFS), up to 12 months|OS, Overall Survival (OS), up to 12 months|Maximum concentration of RD14-01 (Cmax) in peripheral blood (PB) samples, Maximum concentration of RD14-01 (Cmax) in peripheral blood (PB) samples, up to 12 months|Time to Cmax (Tmax) of RD14-01 in peripheral blood (PB) samples, Time to Cmax (Tmax) of RD14-01 in peripheral blood (PB) samples, up to 12 months|Persistence of RD14-01 CAR T cells in peripheral blood samples, Persistence of RD14-01 CAR T cells in peripheral blood samples, up to 12 months
This single-arm, open-label, dose-escalation and dose-expansion study will evaluate the safety and tolerability of RD14-01, ROR1-targeting CAR T cells, in adults with ROR1+ advanced solid tumors. The dose-escalation phase will investigate 3 dose levels to the. The dose-expansion phase will enroll .